Novartis

“Myricx Bio: UK biotech startup - Acquired by Novartis for up to $1.5B”

“Novartis will pay up to $1.5b ($1.1b upfront) to acquire Myricx Bio, a London developer of antibody-drug conjugates that had raised $114m in Series A funding.”

“Momentum shows up in named pharma partnerships (Novartis, Lilly, Johnson & Johnson), a mix of partnered and wholly owned programs, and the company's push to move internal assets toward the clinic.”